{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-033929","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.349191+00:00","generated_at":"2026-05-30T03:25:44.749190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Puma Biotech Q3 net income $20.3M vs $5.8M YoY; raises FY 2024 guidance","bullets":["Product revenue $56.1M (+8.7% YoY); total revenue $80.5M including $24.4M royalty revenue.","GAAP EPS $0.41 diluted; adjusted non-GAAP EPS $0.45 diluted.","FY 2024 net product revenue guidance raised to $187-190M (from $183-190M); net income raised to $15-17M.","Cash & securities $97M at Sept 30; operating cash flow $11M in Q3.","Phase II alisertib trials in SCLC and breast cancer on track; interim data expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-033929","json":"https://secwatch.observer/filing/0001437749-24-033929.json","markdown":"https://secwatch.observer/filing/0001437749-24-033929.md","text":"https://secwatch.observer/filing/0001437749-24-033929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774924033929/0001437749-24-033929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774924033929/pbyi20241106_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:25:44.749190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}